Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.
Welcome back to a new semester of Dissertation Diaries. As a reminder, this is the series where we highlight Ph.D. students ...
As IntraBio works to grow the global treatment market for Aqneursa in Niemann-Pick disease type C, the company is already ...
IntraBio Inc. today announced positive topline results from its pivotal Phase III IB1001-303 clinical trial, "Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Randomized, ...
IntraBio Inc. today announced that the European Commission granted marketing authorization to AQNEURSA® (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Type C (NPC) ...
Johns Hopkins researchers found that delta-type ionotropic glutamate receptors (GluDs) play a key role in regulating neuronal ...
Asianet Newsable on MSN
Hidden brain protein found to control how brain cells communicate
Scientists reveal the GluD brain protein's active role, offering new hope for mental health. Discover how this breakthrough ...
Scientists at Johns Hopkins have uncovered a surprising new way to influence brain activity by targeting a long-mysterious class of proteins linked to anxiety, schizophrenia, and movement disorders.
A “busy person” all his life, 73-year-old Gerard ‘Gerry’ Heaney from Craigavon was diagnosed in 2018 with the rare and ...
SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company” or "Solid”), a life sciences company developing precision genetic ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback